Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1Leukemia, Promyelocytic, Acute 1Childhood Acute Promyelocytic Leukemia With PML-RARA 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

Tretinoin 27Arsenic Trioxide 27Cytarabine 20Cyclophosphamide 14Methotrexate 13Idarubicin 13Busulfan 11Filgrastim 10Etoposide 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mercaptopurine 7Gemtuzumab 7Daunorubicin 7Radiotherapy 6Tacrolimus 5Mitoxantrone 5Clofarabine 5Vorinostat 4Topotecan 4Sorafenib 4Antilymphocyte Serum 4Mycophenolic Acid 3Granulocyte Colony-Stimulating Factor 3Bortezomib 3Azacitidine 3venetoclax 2tamibarotene 2sargramostim 2romidepsin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Promyelocytic, Acute × arsenous acid × Clear all
NCT01409161 2026-05-20

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
151 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡